Connect with us

Health

MSF denied access to Gilead HIV-prevention drug

SHARE:

Published

3 months ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

A dispute between Médecins Sans Frontières (MSF) and Gilead Sciences has entered the public domain after the pharma company refused to sell its game-changing HIV-prevention medicine despite multiple requests. Lenacapavir, a twice-yearly injectable form of PrEP, could be a game changer, especially for people who struggle to access daily medication.

In an open letter Chief Executive Officer, MSF USA, Tirana Hassan and Director, Southern Africa Medical Unit, MSF Southern Africa, Dr Tom Ellman, call on Gilead to review their decision.

“That this drug’s development was supported by public funding - and through the trust of communities who participated in clinical trials, many of them in countries now excluded from affordable access - makes the current restrictions even more unconscionable,” write the MSF officials...

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending